drugset / Trial / NCT02584569
Phase 1 TAK-915 Single-Dose Positron Emission Tomography (PET) Occupancy Study
NaSingle-groupOpen-labelTreatment
Summary
This phase 1 study will be conducted to examine the degree and duration of brain PDE2A enzyme occupancy /target engagement as a function of TAK-915 plasma concentration in order to guide dosing and schedule for future clinical studies in schizophrenia with TAK-915.
Timeline
- Start
- 2015-11
- Primary completion
- 2016-04
- Completion
- 2016-04
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | TAK-915 | Small molecule | 100 mg | Oral |
Indications
No indication recorded.